A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

ID Number 13-0728

Principal Investigator(s)
Sundar Jagannath

Department(s) or Division(s)
Hematology and Medical Oncology


Pharmacyclics, Inc. is studying an experimental new drug called PCI-32765.  An experimental drug is one that is being tested and is not approved by the FDA for sale or use except in research studies such as this one. 

PCI-32765 is a type of drug called a “kinase inhibitor”.  “Kinases” are proteins inside cells that help cells live and grow.  The specific kinase inhibited or “blocked” by the study drug is believed to help blood cancer cells live and grow.  By inhibiting the activity of this specific kinase, it is possible that the study drug may kill the cancer cells or stop them from growing.

The purpose of this study includes finding out if the study drug, given once daily by mouth will slow or stop a person’s cancer from getting worse, and whether the study drug has side effects.


In this study, people with MM, who have previously received treatment and have relapsed or relapsed and have resistant disease will be eligible to participate.


Contact Information
Lisa La
(212) 241-8615

Recruiting Patients: No